ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024 08:00 ET | Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
22157.jpg
Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment
June 08, 2022 04:43 ET | Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...
QMI-Logo-Long-1000px.jpg
Global PARP Inhibitor Market To Grow At A CAGR Of 27.4% Due To Expanding Role Of PARP Inhibitors In Cancer Treatment
July 22, 2020 08:30 ET | Quince Market Insights
Pune, India, July 22, 2020 (GLOBE NEWSWIRE) -- Global PARP Inhibitor Market was valued at USD 924 million in 2018 and predicted to grow at an exponential CAGR of 27.4% during the forecast period....
logo.png
Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program
July 13, 2020 08:28 ET | Oncology Venture A/S
Hoersholm, Denmark (13 July 2020) – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) announced today that it has secured the remaining ownership in its priority PARP...
CC2.png
ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System
December 18, 2019 16:30 ET | ChemioCare
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
September 30, 2019 06:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Cybrexa.png
Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy
May 15, 2019 17:01 ET | Cybrexa Therapeutics
Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
Cybrexa.png
Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity
April 02, 2019 08:00 ET | Cybrexa Therapeutics
Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors   Poster presentation today during AACR Annual Meeting 2019 ...
TESARO® logo_RGB_small.png
TESARO Announces Data Presentations at ESMO 2018 Congress
October 20, 2018 01:30 ET | TESARO, Inc.
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen...
TESARO® logo_RGB_small.png
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:15 ET | TESARO, Inc.
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...